Clinical Trial Search

Primary: Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment — -17.2; -4.9; -29.8; 12.5 pg*hr/mL — p=0.002

Primary: AUC0-144 (Area Under the Concentration-time Curve From Time Zero to 144 Hour Post-dose) — 114386.56; 105377.55 ng*h/mL — p=<0.05

Primary: Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale — 6.03; 5.24; 5.96; 5.31 scores on scale

Primary: Change From Baseline in QTcF at 0.5 Hours — 1.78; -1.22 milliseconds

Primary: Part 1: The Total Urinary Excretion of Alendronate With Alendronate/Vitamin D Combination Tablet Relative to Alendronate Tablet — 197.5; 191.9 micrograms (μg)

Primary: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½ — 27.446; 28.180 hours — p=0.4591

Primary: Tobramycin Tear Concentration Cmax (Maximum Concentration) — 853; 527; 542 µg/mL

Primary: Daily Evening Patient Reported Pain Intensity Scores — 0.14; 1.57 Units on a Scale — p=0.003

Primary: Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI at Time of Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day)…

Primary: Cortisol and Catecholamine Production — 0.107; 0.119; 0.107; 43.5 pg/ml (log 10) — p=0.83

Primary: Maximum Plasma Concentration (Cmax) for Quinine Sulfate — 3,293.84; 3,424.30 ng/mL

Primary: Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin — 7.65; 7.45 μg * hr/mL

Primary: Number of Participants With Dose Limiting Toxicities at Dose Level — 0; 0; 0; 0 participants

Primary: Maximum Plasma Concentration (Cmax) — 1,165.92; 1,202.28 ng/mL

Primary: Maximum Plasma Concentration (Cmax) for Zolpidem Tartrate — 123.61; 131.92 ng/mL